VolitionRx Limited (VNRX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by VolitionRx Limited on April 28, 2026. The report details a material modification to the rights of security holders resulting from a stockholder-approved reverse stock split.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and capital structure changes rather than financial performance.
Material Changes
- Reverse Stock Split: The Board of Directors approved a one-for-twenty reverse stock split of the Company's common stock.
- Effective Date: The split became effective at 12:01 a.m. ET on April 28, 2026.
- Legal Action: A Certificate of Third Amendment to the Second Amended and Restated Certificate of Incorporation was filed with the Delaware Secretary of State on April 27, 2026.
- Fractional Shares: The amendment describes the treatment of fractional shares resulting from the split.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future financial guidance, operational outlook, or specific risk factors beyond the structural change to the stock. The primary contingency noted is the treatment of fractional shares as defined in the Certificate of Amendment.
Investor Verification Checklist
- Verify the exact ratio of the reverse stock split (1-for-20) and its impact on share count and price.
- Confirm the treatment of fractional shares (e.g., cash payout or rounding) as detailed in Exhibit 3.1.
- Check the updated trading status of VNRX on NYSE American, LLC following the April 28, 2026 effective time.
- Review the Certificate of Third Amendment (Exhibit 3.1) for complete legal terms regarding the amendment to Section 6.1 of Article 6.